TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
HCW Biologics ( (HCWB) ) just unveiled an announcement.
On August 19, 2025, HCW Biologics Inc. received notice from Nasdaq that it was non-compliant with the Equity Rule for continued listing. Following a hearing on September 25, 2025, the Nasdaq Hearings Panel granted the company an extension to regain compliance, requiring it to meet all listing rules by February 16, 2026. The company must also notify Nasdaq of significant events affecting compliance and file necessary documentation for review.
The most recent analyst rating on (HCWB) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.
Spark’s Take on HCWB Stock
According to Spark, TipRanks’ AI Analyst, HCWB is a Neutral.
HCW Biologics is currently facing significant financial and operational challenges, as reflected in its low financial performance score. The technical analysis indicates a bearish trend, and the valuation is unattractive due to negative earnings. These factors collectively result in a low overall stock score.
To see Spark’s full report on HCWB stock, click here.
More about HCW Biologics
Average Trading Volume: 1,885,577
Technical Sentiment Signal: Sell
Current Market Cap: $9.34M
See more insights into HCWB stock on TipRanks’ Stock Analysis page.